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Summary
 Background Treatment options for bile duct cancer remain limited due to the large number 
of patients with advanced disease at the time of diagnosis. Radical surgery is pos-
sible in less than 10–15% of these cases. Unresectable bile duct cancers are very 
difﬁ cult to treat with external beam therapy alone due to the proximity of ad-
jacent normal organs and the high doses required to effectively irradiate these 
neoplasms. Indications for brachytherapy include all malignant strictures of the 
bile duct which can be cannulated. Patients should be ﬁ t enough for the proce-
dure and should have been reviewed to conﬁ rm that they are not suitable for re-
section. Combined treatment is possible in patients who are in good condition; 
it is usual to combine bile duct brachytherapy (BT) with external beam radiation 
therapy (EBRT).
 Aim To assess the feasibility of intraluminal palliative pulsed dose rate brachytherapy 
(PDR-BT) in the treatment of locally advanced bile duct cancer.
 Materials/Methods Seventeen patients with advanced inoperable bile duct cancer were treated be-
tween May 2002 and December 2005 in Greatpoland Cancer Centre. Patients were 
disqualiﬁ ed from surgery or radical external beam radiation therapy (EBRT). 
Thirteen patients were treated exclusively with PDR brachytherapy, 4 patients 
were qualiﬁ ed for combined treatment: PDR brachytherapy and palliative EBRT. 
Percutaneous trans-hepatic technique was used to implant a catheter into the bile 
duct. All patients received 25 pulses of 0.8Gy hourly to the total dose of 20Gy. In 
4 cases PDR was repeated after one week. Target Volume encompassed tumour 
visualized at cholangiography and a one or two cm margin taken proximally and 
distally. Dose was prescribed at 10mm from the source axis. For palliative EBRT 
15MV photons were used.
 Results In all 17 cases trans-hepatic technique allowed insertion of the BT catheter into 
the bile duct and safe application of PDR-BT. In 13/17 (76.5%) cases improve-
ment in jaundice was noted at the ﬁ rst check-up after 4 weeks. Median overall 
survival time (OS) was 10 months, longest survival time was 36 months, shortest 
was 2 months. Acute and late complications were not observed.
 Conclusions 1. It was established that the use of pulsed dose rate brachytherapy was feasible and 
had a low early complication rate. A new percutaneous trans-hepatic technique 
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BACKGROUND
Treatment options for bile duct cancer remain 
limited due to the large number of patients with 
advanced disease at the time of diagnosis. Radical 
surgery is possible in less than 10–15% of these 
cases [1–4]. Unresectable bile duct cancers are 
very difﬁ cult to treat with external beam thera-
py alone due to the proximity of adjacent nor-
mal organs and high doses required to effective-
ly irradiate these neoplasms [1,5].
Bile duct carcinoma is rare. It accounts for ap-
proximately 200 new cases annually in Poland; it 
makes up less than 4% of gastrointestinal malig-
nancies. The majority of bile duct carcinomas in-
volve the hepatic duct bifurcation, the common 
hepatic duct, the cystic duct, and the ampulla. 
The tumour can spread along the sinusoids and 
neoplastic destruction of normal cholangioles 
leads to the retention of bile around the mar-
gin of the tumour. Tumour emboli in the portal 
and hepatic veins are common and vascular in-
vasion can occur in up to 90% of cases. The tu-
mour may also metastasize to the lungs, perito-
neum and intra-peritoneal organs. The majority 
of tumours are low-grade cholangiocarcinomas. 
Patients commonly present with obstructive jaun-
dice. The most important diagnostic procedure is 
cholangiography. Staging requires ultrasound and 
CT scans. The only curative treatment is radical 
surgical excision. However, because of the pro-
pensity of cholangiocarcinomas to invade the 
hepatic artery, portal vein and other vital struc-
tures this is only feasible in 10 to 20% of cases 
and is associated with an operative mortality of 
5 to 10% [2,6,7]. Effective palliation is achieved 
by biliary decompression. This is carried out ei-
ther surgically by using bypass procedures such 
as hepaticojejunostomy or nonoperatively by en-
doscopic or percutaneous insertion of biliary en-
doprotheses [1,8,9].
Indications for brachytherapy include all malig-
nant strictures of the bile duct which can be can-
nulated. Patients should be ﬁ t enough for the pro-
cedure and should have been reviewed to conﬁ rm 
that they are not suitable for resection. Combined 
treatment is possible in patients who are in rea-
sonably good condition; it is usual to combine 
bile duct brachytherapy (BT) with external beam 
radiation therapy (EBRT) [5,10–15].
AIM
The purpose of this study was to assess the feasibil-
ity of intraluminal PDR brachytherapy (PDR-BT) 
and trans-hepatic technique of catheter insertion 
in the treatment of locally advanced bile duct can-
cer. We decided to irradiate these patients due to 
the clinical presence of a tumour and due to in-
crease of jaundice. We chose PDR-BT instead of 
HDR- BT because of the short one-day treatment 
time which was accepted by the patients and the 
growing interest in using PDR-BT in treatment of 
different cancers. In view of the short time of ob-
servation and small group of patients we present 
the preliminary results.
MATERIALS AND METHODS
Patients
Seventeen patients with advanced bile duct cancer 
were treated using PDR brachytherapy between 
May 2002 and December 2005 in Greatpoland 
Cancer Centre. In all cases trans-hepatic tech-
nique was used. There were 10 women and 7 
men, at median age of 59.8 years, range from 40 
to 81. Six patients underwent surgical procedures 
 Author’s address: Janusz Skowronek, Department of Brachytherapy, Greatpoland Cancer Center, Garbary 15 Str., 61-866 
Poznań, Poland, e-mail: janusz.skowronek@wco.pl
allowed whole treatment (insertion of catheter, PDR brachytherapy) to be per-
formed in one day. 2. In most cases a satisfactory palliative effect was achieved.
 Key words bile duct cancer • palliative • PDR brachytherapy • radiotherapy
 Full-text PDF: http:/www.rpor.pl/pdf.php?MAN=10308
 Word count: 3469
 Tables: 2
 Figures: —
 References: 34
Preliminary Communication Rep Pract Oncol Radiother, 2007; 12(2): 125-133
126
(prior cholecystectomy) before being referred for 
brachytherapy. In four a palliative surgical proce-
dure such as biliodigestive anastomosis had been 
performed. In twelve patients a stent or endo-
prosthesis was placed. All patients referred for 
brachytherapy were regarded by surgeons as no 
further operable. All of them had been sympto-
matic with jaundice, eleven suffered from pain 
in the upper abdomen, seven from anorexia 
and nausea and in ﬁ fteen patients rapid weight 
loss (up to 15 kg in 2–3 months) had occurred. 
Histological conﬁ rmation of adenocarcinoma was 
obtained in 10 cases: in 8 cases adenocarcinoma, in 
1 case cholangiocarcinoma and in 1 case carcinoma 
solidum adenogenes were diagnosed. In the remain-
ing cases we did not obtain histological materi-
al for diagnosis. The diagnosis of cancer was es-
tablished by radiographic, endoscopic and other 
clinical evidence. Most of the tumours were lo-
cated in the perihilar and common hepatic duct 
(CHD) – 12/17 (70.6%). Summarized clinical 
data are presented in Table 1.
Method of treatment
Brachytherapy was started on the same day 
after insertion of the intraductal catheter. 
Cholangiography was performed to compare 
current status with earlier X-ray ﬁ lms. Treatment 
planning was based on radiography taken with 
the applicator in place and the cholangiogram 
showing the malignant stenosis (Figures 1, 2). 
Cases with stents inserted previously are present-
ed in Figures 3 and 4. The radio-opaque wire had 
markers at intervals which indicated the place-
ment of the radioactive source. An X-ray unit, the 
IBU (Integrated Brachytherapy Unit), was used 
for 3D planning. Target Volume encompassed tu-
mour visualized at cholangiography and a 1 or 
2cm margin taken proximally and distally. The 
Characteristic Number, rate 
Age: Median
 Range
59.8
40–81
Gender: Male
 Female
 7 (41.2%)
 10 (58.8%)
Tumour site: Perihilar and CHD
 CBD
 Diff use*
12 (70.6%)
3
2
Pathologic type: Adenocarcinoma
 Cholangiocarcinoma
  Carcinoma solidum 
adenogenes
 Lack of diagnosis
8
1
1
 7 (41.2%)
Primary/recurrent tumour
Previous surgery
11/6
6
Table 1. Patients’ characteristics.
CHD – common hepatic duct; CBD – common bile duct.
* Included patients with >2 sites of extrahepatic biliary ducts.
Figure 1. Bile duct cancer, bile ducts visible after cholangiography, 
obturated part visible as a break, 5 French brachytherapy catheter 
with radio-opaque wire inside, irradiated length 5cm (between 
black points).
Figure 2. A diff erent patient than in Figure 1, bile duct cancer, 
bile ducts visible after cholangiography, obturated part visible as 
a break, 5 French brachytherapy catheter with radio-opaque wire 
inside, irradiated length 6cm (4cm of obturation and a margin of 
1cm distally and proximally).
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radiation dose was prescribed at 10mm from the 
source axis. The length of the reference isod-
ose encompassed the planning target length as 
closely as possible. PLATO brachytherapy plan-
ning system was used. Treatment plan for EBRT 
was prepared with 3-dimensional treatment plan-
ning system (CadPlan®); 15MV photons were 
used. For PDR brachytherapy a microSelectron 
PDR (Nucletron®) unit was used, with radioac-
tive source 192Iridium, with 1Ci (Curie) nominal 
activity. A 5 French intraluminal catheter was at-
tached to a remote afterloading machine which 
was given pulses of PDR-BT.
Thirteen patients were treated exclusively with 
PDR brachytherapy. PDR brachytherapy was cho-
sen as the method of treatment because of the 
relatively good performance status of all patients 
and for shortening of the overall treatment time 
[16]. They received one fraction of 25 pulses, 
0.8Gy hourly up to 20Gy total dose. Four patients 
received two PDR fractions of 20Gy with a 1-week 
interval because of rapid regression of jaundice 
and satisﬁ ed relief of pain. Four patients with 
reasonably good performance status and with 
relative large tumour thickness were qualiﬁ ed 
for combined palliative treatment (PDR brach-
ytherapy and external beam radiation therapy). 
A dose of 40Gy was delivered to a volume which 
encompassed the porta hepatis, the common bile 
duct and regional nodes.
Trans-hepatic technique
There are two techniques commonly used in 
brachytherapy treatment of advanced bile duct 
carcinoma nowadays. The ﬁ rst is trans-duodenal 
endoscopic technique, the second trans-hepatic 
technique. Percutaneous trans-hepatic technique 
allows the passage of a catheter through the stric-
ture. A transhepatic cholangiogram is initially 
Figure 3. Bile duct cancer with recurrence after insertion of 
prothesis, bile ducts visible after cholangiography, obturated 
part visible as a break
Figure 4. Bile duct cancer with recurrence after insertion of 
prothesis, bile ducts visible after cholangiography, obturated part 
visible as a break, French 5 brachytherapy catheter with radio-
opaque wire inside, irradiated length 5cm (3cm of obturation and 
a margin of 1 cm distally and proximally).
Figure 5. Photo of a patient with a 10F catheter inserted using 
trans-hepatic technique in the bile ducts, a 5 French catheter for 
brachytherapy (dark blue colour) inside.
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performed under ﬂ uoroscopic control; in pa-
tients who have undergone a surgical procedure, 
the cholangiogram can be performed through 
the T-tube. After the site of obstruction is iden-
tiﬁ ed, a ﬂ exible catheter is inserted into the bil-
iary tree to an appropriate depth, under ﬂ uoro-
scopic control. To avoid the catheter changing 
procedure, we used a 10 French catheter, which 
could also be used as a conduit to place the brach-
ytherapy catheter, thus facilitating the procedure 
for both team and patient (Figure 5). A dual-lu-
men catheter or two separate catheters can be in-
serted in another technique, one for lodging the 
radioactive sources and the other for bile drain-
age. Special care must be taken to maintain bil-
iary drainage. Otherwise, the patient will develop 
pain and fever as a result of obstructive cholangi-
tis. The catheter is sutured to the skin.
RESULTS
All patients had an unfavourable prognosis. In all 
17 cases trans-hepatic technique allowed correct 
insertion of a BT catheter and safe use of PDR-BT. 
Complications connected with the technique were 
not observed. In 13/17 cases (76.5%) improve-
ment (complete or partial remission) in grade of 
jaundice was assessed within 4 weeks after brach-
ytherapy. In two cases we noted lack of remission, 
in two other cases deterioration. Decline in per-
formance status was observed during the course 
of brachytherapy in one patient with metastasis 
in the liver, which did not end the treatment, 
and in a second when 4 weeks after the end of 
treatment we noted massive progression in the 
liver. Median overall survival time (OS) was out 
10 months, longest survival time 36 months, and 
the shortest 2 months. These results refer to 11 
patients who were under regular observation in 
the Brachytherapy Department. Acute and late 
complications were not observed. Due to the small 
number of patients in this pilot study, these re-
sults do not reach the level of signiﬁ cance.
DISCUSSION
The vast majority of bile duct tumours are diag-
nosed late, with upper abdominal discomfort, 
general malaise, fever, anorexia and jaundice. 
Tumours of the bile duct are much less com-
mon than hepatocellular carcinoma and the ae-
tiology is unknown. Prognosis is poor and relat-
ed to the extent of spread within the liver and 
regional lymph nodes and to the site of tumour 
[1]. Most bile duct cancer patients are treated 
palliatively.
The role of radiotherapy in this disease has long 
been debated. Since the majority of patients die 
from uncontrolled locoregional disease, postop-
erative adjuvant radiotherapy has been used at 
several centres [4,5,17–19]. Until the mid-1970s 
cholangiocarcinoma was considered to be radiore-
sistant. There were several reasons for this. Firstly, 
cholangiocarcinomas were considered intrinsical-
ly radioresistant. Secondly, the technical problem 
of delivering radical radiation without damaging 
the intestine or liver was formidable. Before the 
advent of radiological techniques for decompres-
sion of the obstructed biliary tract most patients 
were in poor general condition and treatment 
was not attempted. However, during the second 
half of the 1970s a few published reports indicat-
ed that radiotherapy could provide useful palli-
ation and possibly improve survival for patients 
with cholangiocarcinoma. Several reports then in-
dicated that radiotherapy could provide useful 
palliation [12,17]. In some cases external beam 
radiotherapy (EBRT) was thought to have con-
tributed to prolongation of survival [14,19,20]. 
Kopelson et al. reported that obstructive jaun-
dice was relieved in 7 of 8 patients treated for 
extrahepatic bile duct cancer with EBRT [17]. 
Hanna and Rider retrospectively reviewed 17 pa-
tients treated at the Princess Margaret Hospital, 
Toronto [14]. Fourteen patients who received ra-
diotherapy had a mean survival of 12.3 months 
compared with 1.1 months for those who did 
not.
In the 1980s, intraluminal brachytherapy for 
cholangiocarcinoma was introduced and in-
spired considerable enthusiasm. Since most 
cholangiocarcinomas remain localised until a rela-
tively late stage in their natural history, the ability 
to give a high radiation dose to the tumour with-
out jeopardising adjacent radiosensitive structures 
was attractive. The ease with which a radioactive 
source could be placed via transhepatic catheters 
was a further spur to developing the technique. 
The increasing use of percutaneous transhepatic 
catheters by interventional radiologists provided 
a means by which brachytherapy could be given. 
A 192Ir wire could be inserted through these cath-
eters. Such treatment has also been given by in-
sertion of a 192Ir wire through an endoscopically 
placed nasobiliary catheter [21]. Several cen-
tres have reported their results using intralumi-
nal brachytherapy alone or in combination with 
EBRT [5,11,15,18,22–24]. It was difﬁ cult to sep-
arate the effect of biliary decompression on sur-
vival from that of radiotherapy. The median sur-
vival for this procedure is 10 to 12 months and 
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approximately 15% of patients survive for 2 years 
or more. Late effects of treatment are often difﬁ -
cult to distinguish from symptoms due to recur-
rence or blockage of the biliary drain. Blockage 
of the stent or biliary drain is fairly common and 
it may need to be replaced every 3 to 4 months. 
Others have reported improvement in survival 
using this technique.
In 1984 a protocol for treating advanced cholan-
giocarcinoma using both EBRT and BT was in-
troduced at Hammersmith Hospital [25]. An 
accelerated split course of EBRT was used. This 
allowed a reduction in overall treatment time (4 
compared with 5 weeks for conventional fraction-
ation) without concomitant reduction in total ra-
diation dose. Reduction of overall treatment time 
diminishes the opportunity for tumour cell re-
population during treatment, and therefore in-
creases the probability of tumour control for a 
given dose. The fraction size used in the accel-
erated EBRT regimen reported here was either 
2.25Gy (pre 1989) or 2.75Gy. The latter was less 
well tolerated with fewer patients completing 
the prescribed course of treatment. Large frac-
tion sizes were associated with late radiation mor-
bidity. Karani et al. treated 30 patients with hilar 
cholangiocarcinoma by BT alone. Mean surviv-
al time was 16.8 months and this compared fa-
vourably with a mean survival of 8.5 months for 
patients treated by palliative surgery or stenting 
only at the same institution [26]. Fields et al. [5] 
found that eight patients receiving BT in addi-
tion to EBRT had a median survival of 15 months 
compared to 7 months for those receiving EBRT 
only. Seven patients were treated at Stanford 
University Medical Center using a combination 
of EBRT (50.0Gy) and BT (31.0Gy to 60.0Gy) 
[11]. The mean survival was 15.4 months. Fritz 
et al. [10] reported the treatment of 30 patients 
with extrahepatic bile duct cancers using EBRT 
(30.0 to 45.0Gy) and BT (20.0 to 45.0Gy). The 
median survival was 10 months. Mahe et al. [22] 
treated 51 patients; 25 received EBRT, 8 BT and 
17 both EBRT and BT. Median survival for the 
whole group was 12 months. Radiotherapy was 
associated with signiﬁ cant prolongation of sur-
vival in patients undergoing palliative stenting; 
actuarial 1-year survival of those receiving ra-
diotherapy was 38% compared to 9% in those 
in whom radiotherapy was not given. In none 
of these series were patients randomised to re-
ceive radiotherapy or not, so the real efﬁ cacy of 
treatment is difﬁ cult to estimate. Shin et al. [27] 
treated 31 patients with inoperable carcinoma of 
the extrahepatic bile ducts with a combination 
of EBRT and BT. Although locoregional recur-
rence was the most common pattern of failure in 
both groups, no statistically signiﬁ cant difference 
was found in the recurrence rates between those 
who did and did not receive BT (53% for Group 
1 vs. 36% for Group 2; p >0.05). However, a pro-
longation of the median time to tumour recur-
rence was observed in Group 2 patients (5 months 
for Group 1 vs. 9 months for Group 2; p=0.06). 
With a median follow-up of 12 months, the over-
all actuarial 2-year survival rate for Group 2 pa-
tients was signiﬁ cantly better than that for Group 
1 patients (0% for Group 1 vs. 21% for Group 
2; p=0.015). Schleicher et al. [28] treated 30 pa-
tients for extrahepatic proximal bile duct can-
cer with a schedule consisting of EBRT (median 
dose 30Gy) and a HDR-BT boost (median dose 
40Gy) delivered in four or ﬁ ve fractions. 15 pa-
tients in the brachytherapy and nine patients in 
the non-brachytherapy group received additional 
low-dose chemotherapy with 5-ﬂ uorouracil. The 
brachytherapy boost dose improved the effect of 
EBRT by increasing survival from a median of 3.9 
months in the non-brachytherapy group to 9.1 
months in the brachytherapy group. The effect 
was obvious in patients receiving a brachythera-
py dose above 30Gy, and in those without jaun-
dice at the beginning of radiotherapy (p<0.05). 
Takamura A. et al. [29] treated 93 patients with 
unresectable extrahepatic bile duct carcinoma 
with deﬁ nitive radiotherapy. The dose of external 
beam radiotherapy was 50Gy in 25 fractions. Low-
dose-rate 192Ir was delivered at a dose of 27–50Gy 
(mean 39.2). An expandable metallic endopros-
thesis was used to establish an internal bile pas-
sage. The median survival was 12 months, with 
a 1-, 3-, and 5-year actuarial survival rate of 50%, 
10%, and 4%, respectively. Tumour length, he-
patic invasion and distant metastasis signiﬁ cant-
ly affected survival.
Summarized data from published literature are 
presented in Table 2.
Gastrointestinal bleeding is a complication that 
others have reported. Johnson et al. [11] found 
that of 11 patients treated for a variety of malig-
nant causes of biliary obstruction by EBRT and 
BT, three developed upper gastrointestinal bleed-
ing from duodenitis or frank duodenal ulcera-
tion at 4 weeks, 4 months and 7.5 months. The 
risk of gastrointestinal bleeding may be dose de-
pendent. Fritz et al. [10] found that the frequen-
cy of radiogenic ulcers was 23% in patients receiv-
ing BT doses of 37.5 to 40.0Gy and 7.6% in those 
receiving 20.0Gy. Buskirk et al. [3] found 4 of 20 
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patients receiving radiotherapy for either gall 
bladder cancer or cholangiocarcinoma developed 
gastrointestinal bleeding. Three had received 
doses of greater than 55.0Gy to the stomach or 
duodenum. Intestinal obstruction following ra-
diotherapy for cholangiocarcinoma has also been 
reported [33].
These studies were neither randomised nor con-
trolled, and it has not been possible to make a 
deﬁ nitive statement about the efﬁ cacy of this 
technique. The contribution of BT to surviv-
al in cholangiocarcinoma is still uncertain. A ran-
domised controlled trial would require large 
numbers of patients to demonstrate what is like-
ly to be a subtle effect.
It would be difﬁ cult to accrue sufﬁ cient numbers 
because cholangiocarcinoma is rare and many pa-
tients are treated surgically or are deemed un-
suitable for radiotherapy for a variety of reasons. 
Even those patients who are referred for radio-
therapy are a heterogeneous group, having re-
ceived a variety of different treatments before at-
tendance at the oncology clinic. One potential 
beneﬁ t of BT is that it may prevent encroach-
ment of the tumour into the stent and so the ne-
cessity for frequent stent replacements. However, 
stent occlusion itself has become less of a prob-
lem since the introduction of self-expanding met-
al stents [9].
The efﬁ cacy of BT is still uncertain and control-
led, prospective studies are required to address 
this aspect of radiotherapeutic management of 
cholangiocarcinoma. To test whether the results 
of radiotherapy for cholangiocarcinoma can be im-
proved by the use of synchronous chemotherapy 
our current protocol consists of combined chem-
otherapy (5-ﬂ uorouracil) and EBRT. This is a 
strategy that has recently been reported as being 
well tolerated in a Phase I Eastern Cooperative 
Oncology Group trial [34].
In our opinion indications for brachytherapy 
should include all malignant strictures of the bile 
duct which can be cannulated. Patients should 
be ﬁ t enough for the procedure and should have 
been reviewed to conﬁ rm that they are not suit-
able for resection or sole radical external beam 
radiation therapy. In patients who are in reason-
ably good condition, it is usual to combine bile 
duct brachytherapy with external beam radia-
tion. Thirty to 40 Gy are delivered to a volume 
Author Numberof patients EBRT, dose (Gy)
BT, number of 
fractions, fraction 
dose, method
Results of treatment Statistical analysis
Shin et al. [27] 27 36–55 (median 50.4) 1. No2. 3×5Gy HDR
1. RR – 53%
2. RR – 36%
1. MDC – 5 months
2. MDC – 9 months
1. OS (2 y) – 0%
2. OS (2 y) – 21%
 RR – p>0.05
 MDC – p=0.06
 OS – p=0.015
Schleicher et al. [28] 30 median 30 
1. No
2. median 40Gy, 4–5 
fractions, HDR
1. OS – 3.9 months
2.OS – 9.1 months  OS – p<0.05
Eschelmann et al. [30] 11 25–56 15–31Gy LDR MS – 22.6 months n.d.
Kamada et al. [31] 145 1. 40–502. 40–50 
1. No
2. 25Gy LDR
1. MS – 4.3 months
2. MS – 9.3 months n.d.
Gonzalez Gonzalez et 
al. [32] 38
1. 44–68
2. 33–47
1. No
2. 22–25Gy LDR
1. MS – 10.5 months
2. MS – 10.5 months n.s.
Takamura et al. [29] 93 50 27–50Gy (median 39.2) LDR MS – 12 months n.d.
Table 2. Results of combined EBRT and BT - literature review. Regarding the outcome with diff erent treatment schedules, the very 
inhomogeneous patient groups should be taken into account.
In papers of Shin [27], Schleicher [28], Kamada [31] and Gonzalez Gonzalez [32] two diff erent groups are compared.
EBRT – external beam radiotherapy; BT – brachytherapy; HDR – high dose rate brachytherapy; LDR – low dose rate brachytherapy; 
RR – recurrence rate; MDC – median time to tumour recurrence; OS – overall survival; MS – median survival; n.d. – no data; n.s. – not 
signifi cant.
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which encompasses the porta hepatis, the com-
mon bile duct and regional nodes. Evaluation 
for this therapy should be made carefully and 
individually. HDR brachytherapy allow irradia-
tion on an out-patient basis, which makes treat-
ment more accessible. In turn of relatively good 
prognosis PDR (LDR) brachytherapy should be 
taken into consideration. For LDR or PDR irra-
diation a dose of 15 to 20Gy can be given at 1 
cm from the centre of the source axis at a dose 
rate of 0.6 to 0.8Gy/hr. This is combined with 
the prior external beam radiation. For HDR 
brachytherapy, 5Gy per fraction is prescribed 
at 1 cm from the centre of the catheter and can 
be given once or twice daily with a minimum 
of 6 hours between treatments. A total dose of 
20Gy in 4 fractions over 2 or 4 days can be giv-
en if combined with external beam radiation. 
If the patient is being treated by brachytherapy 
alone, 30Gy in 6 fractions over 3 or 6 days may 
be given [1].
We did not ﬁ nd any other reports on using PDR-
BT in treatment of advanced bile duct cancer. 
Our decision to use this technique was based 
on earlier results of LDR brachytherapy. Pulsed 
dose rate (PDR) treatment is a new brachyther-
apy modality that combines the physical advan-
tages of high-dose-rate (HDR) technology (isod-
ose optimization, planning ﬂ exibility, radiation 
safety) with the radiobiological advantages of low-
dose-rate (LDR) brachytherapy (repair advan-
tages) [6]. PDR-BT uses a single stepping source 
of 15–37GBq (0.5–1Ci) of 192Iridium. This pro-
duces treatment dose rates of up to about 3Gy 
per hour which can be delivered (pulsed) each 
hour, 24 pulses per day. PDR-BT consists of us-
ing a stronger radiation source than for LDR 
brachytherapy and gives a series of short expo-
sures of 10 to 30 minutes in every hour to approx-
imately the same overall total dose as with LDR. 
Although low-dose-rate (LDR) BT and high-dose-
rate (HDR) BT have been applied successfully for 
a long time in the treatment of bile duct cancer, 
recent interest in PDR brachytherapy has gradu-
ally expanded its application to the management 
of breast and head and neck cancer, as well as 
bile duct cancer. From a therapeutic viewpoint, 
it seems likely that PDR-BT is a safe modality for 
the treatment of bile duct cancer. Although this 
study has an inherent ﬂ aw because of the retro-
spective analysis and an insufﬁ cient number of 
patients, our observations do suggest that an ap-
proach using PDR-BT has good treatment out-
come in patients with inoperable carcinoma of 
the extrahepatic bile ducts.
CONCLUSIONS
We found that PDR-BT for cholangiocarcinoma was 
feasible. A new percutaneous trans-hepatic tech-
nique allowed whole treatment (insertion of cathe-
ter, planning, PDR brachytherapy) to be performed 
in one day. Until recently, however, no conclusive 
data were available regarding the optimal num-
bers and size of the fractionation and the total ra-
diation dose in BT for malignant bile duct can-
cer. This is why we decided to use similar doses as 
in LDR brachytherapy. We consider the achieved 
palliative effect satisfactory. We consider that in 
patients disqualiﬁ ed for radical treatment one-day 
PDR-BT makes it possible to achieve a palliative ef-
fect which earlier only in some cases was achieved 
pharmacologically. We think that especially in a 
group of patients with recurrence in stents PDR-
BT is a reasonable alternative. Although our tech-
nique provided encouraging results with minimal 
side effects, additional investigation is needed to 
determine the appropriate time-dose fractionation 
scheme through systematic clinical trials.
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